What did @meghanmctavish actually say?
She made three connected claims: that GLP-1 medications reduce inflammation, stabilize blood sugar, and specifically reduce "brain inflammation" while stabilizing serotonin during the luteal phase of the menstrual cycle. She also claimed that one in nine women have PMDD, and that half of those women "try to exit the party early" due to symptom severity.
To her credit, she's not pitching weight loss. She's describing a potential psychiatric and inflammatory mechanism, which is a more sophisticated framing than most GLP-1 content on TikTok. She also mispronounces "luteal" as "lusio," which is minor but worth noting since accurate terminology matters when you're giving medical information to 35,000 viewers.
The core argument is this: PMDD involves a serotonin crash in the luteal phase, GLP-1s reduce neuroinflammation and modulate serotonin signaling, therefore GLP-1s may help PMDD. That chain of logic is not invented. But the confidence with which she states it as settled fact is a problem.
Does the science back this up?
Partially, and with significant caveats. The neuroinflammatory angle has real biological plausibility, but human clinical evidence for GLP-1s specifically improving PMDD is essentially nonexistent right now.
GLP-1 receptors are expressed in the brain, including regions involved in mood regulation like the hippocampus and hypothalamus. Animal studies and some human observational data suggest GLP-1 agonists may reduce neuroinflammatory markers and influence dopaminergic and serotonergic pathways. Mansur et al. (2023, Neuropharmacology) reviewed GLP-1 receptor agonists and neuropsychiatric outcomes and found signals worth investigating, but stopped well short of clinical recommendations. On the PMDD side, research consistently shows that women with PMDD have abnormal sensitivity to normal hormonal fluctuations, with serotonin system dysregulation playing a documented role (Bäckström et al., 2014, Acta Obstetricia et Gynecologica Scandinavica). What does not yet exist is a randomized controlled trial, or even a well-designed observational study, connecting GLP-1 use to PMDD symptom reduction in humans.
What did they get wrong (or right)?
She got the direction of the science right but overstated the certainty. Saying GLP-1s "stabilize serotonin" as if that's an established mechanism in humans is a stretch. The serotonin-modulating effects seen in animal models have not been cleanly replicated or confirmed in human PMDD populations.
She also oversimplifies how GLP-1s work by saying "all it does is reduce inflammation and stabilize blood sugar." That is not what GLP-1 receptor agonists do. They activate a receptor system with widespread effects including gastric motility, appetite signaling, insulin secretion, glucagon suppression, and yes, some neurological effects. Flattening that to two mechanisms is misleading, even if those two mechanisms are relevant to her argument.
The suicide statistic deserves scrutiny. The claim that half of women with PMDD attempt suicide is not supported by the literature as stated. Research does show elevated suicidal ideation in PMDD, with Dennerstein et al. and more recent work suggesting rates of suicidal ideation that are significantly higher than the general female population, but the "half" figure appears to be an overstatement or a misremembered stat. Getting this wrong matters because it could cause unnecessary alarm or, conversely, be dismissed and undermine the real data about suicide risk in this population.
The one-in-nine prevalence figure is reasonable. ACOG estimates range from 3-8% for full PMDD criteria, with broader premenstrual disorder categories reaching higher, so this is in defensible range.
What should you actually know?
If you have PMDD, the evidence-based first-line treatments are SSRIs (used continuously or just in the luteal phase), hormonal suppression approaches, and cognitive behavioral therapy. These have actual randomized trial data behind them. GLP-1 medications do not, for this indication specifically.
That does not mean the hypothesis is worthless. If you are already on a GLP-1 for another reason and you notice your PMDD symptoms improving, that is an observation worth discussing with your prescriber. Some clinicians are tracking anecdotal reports like the ones driving this TikTok trend. But anecdote is not evidence, and a medication with a real side effect profile (nausea, vomiting, potential thyroid risks in predisposed individuals, gastrointestinal issues that can be severe) should not be started off-label for a condition where we have no trial data.
The neuroinflammation hypothesis for PMDD is genuinely interesting. Inflammation during the luteal phase has been documented in some research (Roomruangwong et al., 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry). Whether targeting that pathway with a GLP-1 produces clinically meaningful relief in humans is a question that needs a proper trial, not a TikTok comment section.
- Talk to a gynecologist or psychiatrist familiar with PMDD before considering any off-label treatment.
- SSRIs remain the most evidence-supported pharmacological option for PMDD.
- If you are already prescribed a GLP-1 and suspect it is affecting your cycle symptoms, document it and report it to your prescriber.